{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:13:41Z","timestamp":1784175221636,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR079572"],"award-info":[{"award-number":["AR079572"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK134408"],"award-info":[{"award-number":["DK134408"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtm.2025.101567","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:28:31Z","timestamp":1755556111000},"page":"101567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["High-potency MyoAAV capsids enhanced skeletal muscle correction in a mouse model of GSD IIIa"],"prefix":"10.1016","volume":"33","author":[{"given":"Kuo-An","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-oh","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Barzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Bissig-Choisat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Dimiter","family":"Bissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-0025","authenticated-orcid":false,"given":"Baodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101567_bib1","series-title":"GeneReviews((R))","article-title":"Glycogen Storage Disease Type III","author":"Schreuder","year":"1993"},{"key":"10.1016\/j.omtm.2025.101567_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2025.101567_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","article-title":"Glycogen storage disease type III diagnosis and management guidelines","volume":"12","author":"Kishnani","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2025.101567_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2006.09.022","article-title":"Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?","volume":"46","author":"Demo","year":"2007","journal-title":"J. Hepatol"},{"key":"10.1016\/j.omtm.2025.101567_bib5","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/s41436-019-0561-7","article-title":"Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring","volume":"21","author":"Halaby","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2025.101567_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/jimd.12355","article-title":"Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects","volume":"44","author":"Berling","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2025.101567_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/GIM.0b013e3181e0e979","article-title":"Echocardiographic manifestations of Glycogen Storage Disease III: Increase in wall thickness and left ventricular mass over time","volume":"12","author":"Vertilus","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2025.101567_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ymgme.2017.08.010","article-title":"Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa","volume":"122","author":"Decostre","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2025.101567_bib9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0022-3476(84)80075-X","article-title":"Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy","volume":"105","author":"Slonim","year":"1984","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtm.2025.101567_bib10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1203\/PDR.0b013e318232154f","article-title":"Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet","volume":"70","author":"Valayannopoulos","year":"2011","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.omtm.2025.101567_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-014-0196-3","article-title":"Glycogen storage disease type III: modified Atkins diet improves myopathy","volume":"9","author":"Mayorandan","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2025.101567_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000509335","article-title":"Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa","volume":"76","author":"Olgac","year":"2020","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.omtm.2025.101567_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.omtm.2020.05.034","article-title":"A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme","volume":"18","author":"Lim","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101567_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152970","article-title":"Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice","volume":"7","author":"Lim","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101567_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/acg2\/4639392","article-title":"Long-Term Correction of Murine Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase","volume":"2025","author":"Liao","year":"2025","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101567_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib19","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101567_bib21","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","article-title":"Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV","volume":"28","author":"Morales","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101567_bib24","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101567_bib25","first-page":"804","article-title":"Characterization of a canine model of glycogen storage disease type IIIa","volume":"5","author":"Yi","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2025.101567_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ymgme.2014.02.005","article-title":"Mouse model of glycogen storage disease type III","volume":"111","author":"Liu","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2025.101567_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0815-2","article-title":"Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment","volume":"7","author":"Lafor\u00eat","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtm.2025.101567_bib28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1373\/clinchem.2011.178319","article-title":"Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases","volume":"58","author":"Sluiter","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.omtm.2025.101567_bib29","article-title":"Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort","volume":"23","author":"Piraud","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2025.101567_bib30","article-title":"A human liver chimeric mouse model for non-alcoholic fatty liver disease","volume":"3","author":"Bissig-Choisat","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.omtm.2025.101567_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46017-0","article-title":"A humanized mouse model for adeno-associated viral gene therapy","volume":"15","author":"Barzi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101567_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtm.2025.101567_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101567_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1163427","article-title":"Pathological modeling of glycogen storage disease type III with CRISPR\/Cas9 edited human pluripotent stem cells","volume":"11","author":"Rossiaud","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtm.2025.101567_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172018","article-title":"A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III","volume":"134","author":"Gardin","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101567_bib37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1089\/hum.2010.055","article-title":"Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale","volume":"21","author":"Lock","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101567_bib38","article-title":"A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism","volume":"8","author":"Barzi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101567_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution\u2013electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:06:05Z","timestamp":1772903165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2329050125001627"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101567","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-potency MyoAAV capsids enhanced skeletal muscle correction in a mouse model of GSD IIIa","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101567"}}